Loading...
XNAS
ABEO
Market cap365mUSD
Jul 22, Last price  
6.42USD
1D
-1.68%
1Q
16.30%
Jan 2017
-94.71%
Name

Abeona Therapeutics Inc

Chart & performance

D1W1MN
XNAS:ABEO chart
P/E
5.14
P/S
62.87
EPS
1.25
Div yield, %
—
Shrs. gr., 5y
77.94%
Rev. gr., 5y
-10.26%
Revenues
6m
057,000291,000352,000481,0001,848,0004,404,0002,042,000925,0001,040,000889,000837,0002,998,000010,000,0003,000,0001,414,0003,500,00005,820,000
Net income
71m
P
-12,874,000-21,744,000-31,431,000-17,340,000-7,537,000-2,532,000-10,532,0004,449,000-26,778,000-14,526,000-21,873,000-27,319,000-56,671,000-76,282,000-84,234,000-84,936,000-39,696,000-54,188,000-63,734,00071,183,000
CFO
-76m
L+36.26%
-1,958,0004,843,000-6,560,000-2,248,000-6,860,000-7,609,000-3,955,0001,000-1,611,000-10,423,000-13,014,000-22,935,000-39,111,000-62,820,000-35,019,000-65,665,000-43,483,000-37,009,000-56,015,000-76,326,000
Dividend
Mar 31, 20000.593 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.
URL
https://abeonatherapeutics.com/
IPO date
Sep 19, 1980
Employees
57
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT